1 – 3 of 3
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
A randomized phase II/III study of naptumomab estafenatox + IFNα versus IFNα in renal cell carcinoma : Final analysis with baseline biomarker subgroup and trend analysis
(
- Contribution to journal › Article
- 2008
-
Mark
Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab
2008) 23rd Annual Meeting of the International-Society-for-Biological-Therapy-of-Cancer In Journal of Immunotherapy 31(9). p.937-938(
- Contribution to journal › Published meeting abstract